Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
ZacksThe FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).